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ABSTRACT 
Intravenous iron formulations are widely used in medical practice for a quick recovery of body iron 
depletion. One of the most commonly used formulations is Venofer®, a  compound of iron oxide nanoparticles 
comprising a core of iron in the ferric state and a polysaccharide coating of sucrose aimed to limit the release 
of non-transferrin bound iron (NTBI) into the bloodstream. Although clinically proven as a safe drug, its 
putative effect on T lymphocyte activation and proliferation has never been properly addressed. Several pieces 
of evidence suggest that T lymphocytes may have an important role in iron homeostasis by limiting the inherent 
toxicity of excessive iron in circulation. In patients with Hereditary Haemochromatosis (HH), a genetic iron 
overload disorder, it has been consistently demonstrated that the presence of T lymphocytes in larger numbers 
helps limiting the clinical repercussion of iron toxicity. More recent studies have shown that these cells are 
able to incorporate this metal particularly in the case of iron overload, and thus protect from the accumulation 
in other organs.  
The present study was aimed to analyze the effect of Venofer® on the in vitro proliferation of T 
lymphocytes and to compare this effect in normal subjects and in HH patients. For that purpose, we cultured 
peripheral blood lymphocytes obtained from 6 normal healthy controls and 6 HH patients and used flow 
cytometry to quantify cell cycle and apoptosis parameters in the cultured lymphocytes after exposure to 
Venofer®. In addition, we evaluated the impact of Venofer® on the iron-mediated bleomycin induced 
genotoxicity as measured by chromosome instability in cytogenetic studies. The estimated proliferative index 
obtained with cytogenetic studies was also analysed. 
The results obtained showed that Venofer® can induce a G0/G1 cell cycle arrest in cultured 
lymphocytes obtained from normal healthy individuals, an effect that seems to be related with the proliferative 
index, but was independent from apoptosis, whose markers were not significantly changed.  That effect, 
however, was not observed in cultured cells obtained from HH patients. The evaluation of the impact of 
Venofer® on the iron-mediated bleomycin induced genotoxicity was not conclusive. It was hampered by an 
unexpected and still not clarified effect of the compound in the culture medium, with a significant decrease in 
the percentage of chromosome breaks. 
In conclusion, the present study supports the hypothesis of a relevant biological response of T 
lymphocytes to Venofer®, which is somehow altered in HH patients, suggesting the existence of some adaptive 
mechanism in this genetic condition. Further studies are needed not only to characterize the molecular 
mechanisms involved in the lymphocyte response to Venofer® in vitro, but also to address the in vivo 
implications of these findings.  
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RESUMO 
As formulações de ferro endovenoso são amplamente utilizadas na prática clínica para uma 
recuperação rápida de estados de depleção. Uma das formulações mais vulgarmente utilizadas é o Venofer®, 
constituído por nanopartículas de óxido de ferro formadas por um núcleo de ferro no seu estado férrico e um 
revestimento polissacárido de sacarose destinado a limitar a libertação de ferro não ligado à transferrina (NTBI) 
para a circulação. Embora clinicamente comprovado como um fármaco seguro, o seu presumível efeito sobre 
a ativação e proliferação dos linfócitos T nunca foi devidamente avaliado. Várias evidências sugerem que os 
linfócitos T podem ter um papel importante na homeostasia do ferro através da limitação da toxicidade inerente 
ao excesso de ferro em circulação. Em doentes com a Hemocromatose Hereditária (HH), um distúrbio genético 
de sobrecarga de ferro, tem sido consistentemente demonstrado que a presença de linfócitos T em números 
elevados ajuda a limitar as repercussões clínicas da toxicidade do ferro. Estudos mais recentes têm mostrado 
que estas células são capazes de internalizar este metal particularmente em casos de sobrecarga de ferro e, 
assim, impedir a sua acumulação nos diferentes órgãos. 
O objetivo deste estudo foi analisar o efeito do Venofer® na proliferação in vitro de linfócitos T e 
comparar esse efeito entre indivíduos normais e doentes com HH. Para tal, foram realizadas culturas de 
linfócitos T do sangue periférico obtidas a partir de 6 controlos saudáveis e 6 doentes com HH. Os parâmetros 
do ciclo celular e apoptose nos linfócitos T em cultura após exposição ao Venofer® foram avaliados através 
de técnicas de citometria de fluxo. Além disso, através da observação parâmetros citogenéticos de instabilidade 
cromossómica foi possível avaliar o impacto da Venofer® na genotoxicidade induzida pela bleomicina. Foi 
também possível calcular o índice proliferativo através de estudos citogenéticos, em todas as condições de 
cultura. 
Os resultados obtidos mostraram que o Venofer® pode induzir uma paragem nas fases G0 / G1 do 
ciclo celular de linfócitos T de indivíduos saudáveis normais cultivados in vitro, um efeito que parece estar 
relacionado com o índice proliferativo, mas que é independente da apoptose, cujos valores não se mostraram 
significativamente alterados. Este efeito, no entanto, não foi observado em culturas de células obtidas a partir 
de doentes com HH. A avaliação do impacto do Venofer® na genotoxicidade induzida pela bleomicina não 
foi conclusiva uma vez que a ação da bleomicina foi marcadamente afetada por um efeito inesperado e ainda 
não clarificado do composto no meio de cultura, com uma diminuição significativa na percentagem de quebras 
cromossómicas. 
Em conclusão, o presente estudo suporta a hipótese de uma resposta biológica relevante dos linfócitos 
T à ação do Venofer®, resposta que está de alguma forma alterada em doentes com HH, sugerindo a existência 
de algum mecanismo adaptativo nessa condição genética. São necessários mais estudos para caracterizar os 
mecanismos moleculares envolvidos na resposta in vitro dos linfócitos T ao Venofer®, e para compreender as 
implicações in vivo destes achados. 
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Introduction 
Intravenous iron formulations 
The use of intravenous iron nanoparticles complexed with mono or polysaccharides has been 
recognized as an excellent therapeutic option for a quick recovery of iron depletion (1). Although oral 
administration can be a simple and inexpensive way to increase iron stores in the body (2), it is associated 
with some undesirable effects such as gastrointestinal intolerance, slow absorption with decreased iron 
delivery to tissues and consequently keeping iron body stores low (3). Iron deficiency is one of the most 
prevalent nutritional deficiencies worldwide and a major cause of anaemia, hence the great importance of 
its therapeutic correction (4). The two most commonly used formulations available on the Portuguese 
market for intravenous iron administration are Venofer® and Ferinjet®. These two preparations contain 
iron oxide nanoparticles comprising a core of iron in the ferric state and a polysaccharide coating consisting 
of sucrose or carboxymaltose, respectively (5). Both formulations are significantly superior to oral iron 
administration concerning their potential to increase serum haemoglobin (6; 7), having a good safety profile 
and a low potential risk of hypersensitivity reactions (8). However some anaphylactic reactions may occur 
with these formulations, constituting its main risk (9). These hypersensitivity reactions are triggered mainly 
by the polysaccharide coating (10). Because of its lower cost, Venofer® is preferentially used in the current 
clinical practice in Portugal. 
The carbohydrate coating of iron oxide particles essentially aims to limit the toxicity of these 
formulations, reducing the release of non-transferrin bound iron (NTBI) into the bloodstream, a potentially 
toxic form of iron (11). The biological use of intravenous iron by cells occurs predominantly after the 
uptake of the iron particles by reticuloendothelial macrophages, which subsequently release it to the 
bloodstream bound to transferrin or store it intracellularly for later use (12). It has been already 
demonstrated, however, that the fraction of iron in its free form present in these formulations can exert 
biological activity and may be responsible for its potential toxic effects (13). This fraction of labile iron is 
not dissolved in the nanoparticles and is believed that can be easily transferred to transferrin in the 
bloodstream (14). In addition, it can still be found on NTBI form and be an intervenient in redox reactions 
(15). 
NTBI can be captured in a non-specific manner by certain organs such as liver or heart and cause 
tissue damage by catalysing a series of reactions that increase oxidative stress in cells (16). It also exerts its 
effect by increasing microorganisms’ proliferation (17) and depressing neutrophil function (18). In the past, 
it was common the administration of iron gluconate formulations, whose particles have a lower molecular 
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weight leading to a further increase of non-transferrin-bound iron due to a rapid release of biologically 
active iron into bloodstream (19). Because of that, they are not commonly used nowadays. 
Systemic iron homeostasis 
Iron metabolism in the body is mainly governed by four cell types. The erythroid precursors are the 
major cells utilizing iron, which is a key element for haemoglobin synthesis. These cells express high levels 
of the carrier protein transferrin receptor 1 (TfR1), which mediates the membrane transport of transferrin-
bound iron. It is believed that only transferrin-bound iron, and not NTBI, can be used in heme synthesis 
(20). This concept, however, can be challenged by the recent demonstration of a strong effect of IV iron 
oxide nanoparticles on a rapid increase in haemoglobin levels in patients submitted to orthopaedic surgery 
(21). In this study, the time required for the increase in haemoglobin levels is too short to be explained 
solely by the reticuloendothelial system recycling mechanisms, suggesting that there is a different 
mechanism allowing rapid iron arrival to erythroid precursors. Erythropoietic activity is critical to regulate 
hepcidin levels. Hepcidin, known as “hypoferremia hormone”, is a peptide hormone produced and released 
by hepatocytes which controls iron serum values. It acts by down-regulating the ferroportin-mediated 
release of iron into the bloodstream. Hepatocytes constitute an important site of iron storage in the form of 
ferritin. Under conditions of elevated transferrin saturation, as in iron overload disorders, the liver is one of 
the first organs to be affected since NTBI is a major contributor to iron loading in hepatic cells. Enterocytes 
control iron absorption, an important regulation point of serum iron levels highly regulated and controlled 
by hepcidin. This process occurs mainly on the duodenum and is mediated by two membrane-proteins 
transporters: divalent metal transporter 1 (DMT1) and ferroportin. DMT1 is localized in apical membrane 
of duodenal enterocytes and carries ferrous iron into the cell. Export of iron to circulation occurs through 
the basolateral transporter ferroportin. In turn, reticuloendothelial system macrophages have a major role 
in hepcidin-mediated iron storage and recycling as they can phagocyte senescent erythrocytes (22) and 
export the iron back to the circulation through ferroportin in response to the levels of hepcidin (23).  
The existing information about the role of lymphocytes in iron metabolism is still scarce. Recently, 
it has been proposed that this specific type of cell may have an important role in the protection against iron 
toxicity, particularly in its form of NTBI, which is found in the bloodstream in conditions of iron overload. 
The ability of T lymphocytes to capture NTBI was first demonstrated in vitro, suggesting that these cells 
play a physiological role in the uptake of this form of NTBI, limiting their toxicity. The iron uptake is 
probably mediated by a carrier, which hasn’t been identified yet (24). Evidence for the in vivo implications 
of NTBI uptake by T lymphocytes has been demonstrated more recently in animal models (25). 
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T lymphocytes in Hereditary Haemochromatosis 
The importance of T lymphocytes in iron metabolism has been well recognized in iron overload 
disorders such as Hereditary Haemochromatosis (HH). This entity comprises a group of different types of 
the disease with a similar pathophysiology, characterized by a deficiency in the mechanism of hepcidin-
mediated down-regulation of ferroportin. Clinically, the principal biochemical markers of HH consist in an 
increase in transferrin saturation associated with an increased serum ferritin, this reflecting the 
histopathological evidence of increased iron deposits in different tissues. In most cases, patients present 
symptoms later in life with earliest clinical symptoms in men. It’s most common form, Type I HH, also 
known as HFE-associated HH, results from a mutation in the HFE gene consisting in the substitution of the 
tyrosine amino acid by cysteine  at position 282 of the peptide chain (p.Cys282Tyr). Most cases of HH 
occur in individuals homozygous for this mutation and a fewer cases correspond to compound heterozygous 
individuals with other rare mutations in the HFE gene. The disorder is transmitted to the offspring in an 
autosomal recessive manner. Besides the HFE gene, there are also other iron-related genes that, when 
mutated, may be responsible for other types of HH (26). 
Iron overload as a result of the HFE gene mutation manifests as a clinically heterogeneous disorder 
among different patients. The factors explaining this heterogeneity are still not fully understood and this is 
a subject of intense research. It has been recognized, for a very long time, the association between low 
levels of T lymphocytes and the severity of the iron overload clinical repercussions in HH. Part of this 
phenotypic variability is explained by the numbers of peripheral blood CD8+ T lymphocytes. Patients with 
low numbers of these cells presents a more severe expression of the disease, with high values of total body 
iron stores and the presence of more symptoms associated with the disease (27)(28). It was shown that 
relevant genetic information associated with the transmission of CD8+ lymphocyte numbers is located at 
the chromosomal region of MHC class I (29). This is supported by the recent finding of two different MHC 
associated haplotypes which correlate with the clinical manifestations of iron overload: one of them is 
associated with reduced levels of CD8+ T lymphocytes with less severe clinical signs, while the other is 
associated with high levels of CD8+ T cells and these patients exhibit mild clinical expression of the disease 
(30). However, this correlation is not observed globally, precluding the use of this molecular marker as a 
prognostic factor in HH (31). Currently, some studies are in progress in an attempt to identify a regulatory 
gene for the setting of CD8+ T lymphocyte numbers in the MHC class I region, which may be somehow 
utilized as a predictive molecular marker of the severity of clinical manifestations in HH disease.  
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Iron oxide nanoparticles and T lymphocytes 
The interest on iron oxide nanoparticles has been present in clinical research for a long time, but it 
has exploded in the last few years.  Its use now extends well beyond the classical application as an 
intravenous therapeutic drug to many other applications such as cell labelling on Magnetic Resonance 
Image (MRI) imaging, gene or drug delivery carrier, etc (32; 33). In this case the role of lymphocytes in 
the distribution of iron is also unclear. Cell mapping techniques showed that after some time in circulation, 
nanoparticles less than 20nm in diameter may appear at the level of the lymph nodes (34). It is believed 
that this accumulation in the lymph nodes is mainly due to vascular permeability of the vessels endothelium 
in the lymph nodes (35). However, large amounts of iron are found in the follicular regions of nodes, where 
lymphocytes are the predominant cell type (36; 37), suggesting a role for these cells in the removal of iron 
from the bloodstream. It is of note that intravenous iron preparation most frequently used, Venofer® and 
Ferinject® feature dimensions less than 10nm in diameter (5). There is growing evidence that lymphocytes 
are able to incorporate iron oxide nanoparticles is now coming into light. Siegers et al. (38) demonstrated 
that it is possible to label human gamma delta T cells, a special subset of T lymphocytes, for cellular MRI 
using an ultrasmall superparamagnetic iron oxide contrast agent Feraheme® to track the cells on MRI. 
Feraheme® is an intravenous product utilized to correct iron depletion anaemia. It consists of a 
superparamagnetic iron oxide core coated with polyglucose sorbitol carboxymethylether. Through electron 
microscopy (EM) it was possible to confirm the presence of clusters of iron oxide nanoparticles in the 
cytoplasm of labelled gamma delta T cells as well as access to the cytotoxic effect of iron overload in these 
cells. Furthermore, cells labelled with Feraheme® could be detected in vitro via MRI. Other studies have 
also demonstrated the ability to label T lymphocytes using iron oxide nanoparticles (39). 
Although, in theory, the administration of intravenous iron could lead to toxic effects associated 
with circulating NTBI, namely an increased oxidative stress and inflammation, as already described in 
animal models (40), it has been widely used in humans without known side effects besides rare 
hypersensitivity reactions. As a matter of fact, a study in patients undergoing surgical repair of 
pretrochanteric femur fracture, who received preoperatively 200 to 300 mg of intravenous iron sucrose - 
Venofer®, it was observed that the postoperative infection rate in these patients was 50% lower relative to 
the control group (21). However this study presents some methodological limitations as a result of a low 
sampling. Similarly, a prospective multicentre cohort study in haemodialysis patients receiving intravenous 
iron supplements showed no relationship between the incidence of bacteraemia and serum ferritin levels as 
well as the total dose of intravenous iron administered (41). These data argue against the potential to 
increase the proliferation of microorganisms favoured by increased levels of iron (17). Other studies using 
animal models have also shown that injection of iron nanoparticles weakened antigen-specific immune 
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responses including antibody production and functionality of T lymphocytes (42). A similar study has also 
demonstrated a decrease in delayed hypersensitivity reactions with suppression of Th1 lymphocytes 
functionality and infiltration at tissue level as well as macrophages as a result of injection of iron 
nanoparticles (43). 
Since the role of lymphocytes in iron homeostasis remains poorly understood, it is pertinent to pose 
the following question: how can iron oxide nanoparticles influence the biology of these cells and if this is 
altered in HH?  
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Preliminary evidence support 
 Preliminary work at the Cytogenetics Laboratory (CgL) in ICBAS has shown that treatment of 
proliferating T lymphocytes with uncoated iron oxide nanoparticles, or polyacrylic acid-coated iron oxide 
nanoparticles induces alterations in the proliferative cell profile. However no experiments have ever been 
performed with Venofer®. 
 There is also preliminary evidence, from the same laboratory, that lymphocytes from HH patients 
have a different response to the bleomycin (BLM) genotoxicity test relative to normal controls. This test is 
based on the effect of BLM on DNA damage mediated by iron mobilization therefore providing an indirect 
measure of intracellular iron. These preliminary experiments support the hypothesis that lymphocytes of 
HH patients and controls may have a different iron handling profile and could have a different response to 
Venofer®. 
Problems 
Recently, there have been several evidences that T lymphocytes play an active role in body iron 
regulation, particularly in iron overload diseases. However, most of the mechanisms underlying this 
regulation as well as the effect of injected iron in T lymphocytes remains uncover. For example, it is still 
unknown the scientific basis to support the fact that intravenous iron decreases the infection rate when 
several studies indicate that this metal increases the proliferation of microorganisms. 
It is now evident that T lymphocytes have the ability to uptake some forms of NTBI and it is also 
possible to label this type of cells with iron oxide nanoparticles. Preliminary work at the CgL in ICBAS 
confirmed the T lymphocytes’ capacity to uptake iron oxide nanoparticles and also showed the influence 
of these particles in cell cycle. No experiments have ever been performed with iron oxide nanoparticles that 
are used in clinical practice, such as Venofer®.   
Questions 
 Do T lymphocytes handle sucrose-coated iron oxide nanoparticles (Venofer®) in vitro? 
 Does the T lymphocytes cell cycle change in the presence of sucrose-coating iron oxide nanoparticles 
(Venofer®) in vitro? 
 Do HH patients differ from normal controls in the capacity of T lymphocytes to handle iron oxide 
nanoparticles? 
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Hypotheses of work 
There are two hypotheses tested in this study: 
1. That iron oxide nanoparticles, such as Venofer®, are internalised by T lymphocytes and, by altering the 
intracellular iron levels, may have a biological impact either by promoting a cellular response to oxidative 
stress or by influencing their proliferation rate.  
2. That the putative response of lymphocytes to Venofer® may be somehow different in HH, not only 
because this is a genetic disorder where increased iron levels are already found in circulation, but also 
because the disorder is characterised by the finding of abnormalities in T lymphocytes which are related to 
the severity of iron overload. 
Study aims 
General aims of this work: 
The present work is aimed to help clarifying some of the issues related to the role of T lymphocytes 
in iron metabolism by elucidating the effect of intravenous iron formulations often used in the clinical 
practice in the in vitro proliferation of T lymphocytes. It´s also an objective to compare the biologic 
response of T lymphocytes from normal subjects with that of patients with HH, in an attempt to better 
characterize some previously found evidence of the role of these cells on the disease. 
Specific aims of this work: 
 To ascertain if iron oxide nanoparticles in Venofer® are internalized by T lymphocytes. 
 To determine in which intracellular compartment can we find these particles and what is their 
constitution inside the cell. 
 To evaluate if polysaccharide coating of iron oxide nanoparticles persist intact when they are 
internalized by T lymphocytes. 
 To determine the percentage T lymphocytes in the different phases of cell cycle in the presence of 
iron oxide nanoparticles. 
 To calculate the proliferative status and chromosome instability of T lymphocytes in the presence 
of iron oxide nanoparticles. 
 To explore the response to the bleomycin genotoxicity test as an indirect measure of intracellular 
iron. 
 To perform all experiments T lymphocytes obtained from patients with HH in comparison to normal 
healthy controls. 
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Intervenients 
Institutions, Departments and Services 
 Centro Hospitalar do Porto (CHP) / Hospital de Santo António (HSA)  
o Department of  Medicine (DM) / Clinical Haematology Service  (SHC)  
 Institute for Molecular and Cell Biology (IBMC) 
o Basic & Clinical Research on Iron Biology (BCRIB) 
o Histology and Electron Microscopy Service (HEMS) 
 Abel Salazar Institute of Biomedical Sciences (ICBAS) / University of Porto (UP) 
o Microscopy Department  / Cytogenetics Laboratory (CgL) 
Research team 
Constitution 
Student 
 Daniel Mendes: student in the “Disciplina de Inciação à Investigação Clínica” (DIIC) - Master in 
Medicine (MIM) ICBAS / UP. 
Supervisor 
 Graça Porto (M.D. PhD): Specialist in Imunohemotherapy, Head Consultant, Service of Clinical 
Haematology / Haemochromatosis consultation HSA/CHP. Research Group Leader at IBMC (Basic and 
Clinical Research on Iron Biology), Invited Full Professor at ICBAS/UP, Pathology and Molecular 
Immunology Department.  
Co-supervisor 
 Beatriz Porto (PhD):  Director of the Cytogenetics Laboratory and assistant Professor at ICBAS/UP.  
Discipline supervisor 
 Margarida Lima (M.D. PhD): Specialist in Imunohemotherapy, graduated orderly, Service of Clinical 
Haematology of HSA/CHP; invited assistant Professor at ICBAS/UP; regent of DIIC. 
Colaborators 
 Rui Fernandes: Group Leader at Histology and Electron Microscopy Service, IBMC/UP. 
 Sónia Fonseca, clinical analysis technician, Cytometry Laboratory of Service of Clinical Haematology, 
HSA/CHP. 
 Rosa Sousa, research fellow at Laboratory of Cytogenetics, Department of Microscopy, ICBAS/UP. 
Functions and responsibilities 
The conception and formulation of the proposal, as well as the execution of the project are the 
responsibilities of the student.  
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The supervisor will monitor the formulation of the proposal, the execution of the project and the 
analysis and interpretation of the results.  
The discipline supervisor will supervise all the steps of the project, including the conception, the 
implementation, and the presentation of the results.  
The following investigators will collaborate in specific tasks of the project, as described forward. 
Time dedicated to the project 
First and last names Function Person * Month 
Daniel Mendes Student 10%*22 = 2.20 
Graça Porto Supervisor 2.5%*22 = 0.55 
Margarida Lima Discipline supervisor  2.5%*22 = 0.55 
Beatriz Porto Cytogenetic supervisor 2.5%*22 = 0.55 
Sónia Fonseca Collaborator 2.5%*2 = 0.10 
Rosa Sousa Collaborator 2.5%*2 = 0.10 
Rui Fernandes Collaborator 2.5%*2 = 0.05 
Total 4.10 
Conditions and motivations to conducting the study 
Installed capacities and available resources 
The conditions necessary to execute the project are ensuring.  The SHC at HSA/CHP has all the 
necessary equipment to carry out the experiments to study cell cycle alterations and in CgL at ICBAS/UP 
we can perform the BLM genotoxicity tests. However we need to purchase the reagents that will be used 
in the experiments. Similarly the HEMS laboratory at IBMC has all the necessary equipment to use the 
TEM / EDX technology. Both laboratories have performed similar experiments in their facilities. 
Research tem merit 
The supervisor of the project belongs to BCRIB, a team of researchers that has a long track record 
of publications that have the common propose of clarify the reciprocal interactions between iron 
metabolism and the immune system, mainly the role of CD8+ T lymphocytes in cases of iron overload 
(utilizing HH as model). Research work conducted by the team has already shown the ability of T 
lymphocytes to internalize iron, but there is still much to discover. In a recent paper of the supervisor and 
her team it is clarified the that T lymphocytes have a major role in NTBI in vivo handling, limiting their 
toxicity and acting as protective cells in iron overload disorders as HH. 
Personal motivations to conducting the study 
To acquire skills in terms of scientific reasoning. 
To develop the competence of working with a research team with structured functions and 
responsibilities. 
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To contact with laboratory techniques and with the dynamic between clinic and primary sciences in 
the scope of medicine. 
To get personal accomplishment. 
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Methodology 
Literature review criteria  
In the literature review we used scientific journal articles indexed in MEDLINE data basis using 
PubMed as the search engine. We tried to use the most updated knowledge, but the articles date doesn’t 
constitute a search criterion. The following key words were used in the scientific search: “Iron oxide”, 
“nanoparticles”, “intravenous”, “T lymphocytes” and “Hereditary Haemochromatosis”. We selected only 
original and review articles in English language. We also included specific articles that the project 
supervisor has advised. 
Study design 
Type of study 
Local: National and institutional study. 
Type: Analytic, observational, cross-sectional and case-control study. 
Nature: Clinical and laboratorial study. 
Phases of the study 
The study will be conducted in two distinct phases: 
a) In the first phase the cell cycle experiments and BMC genotoxicity tests will be performed. 
b) In the second phase the results in samples where cells will have greater iron-uptake, measured 
indirectly by BLM genotoxicity test, will be validated with measurements of intracellular iron distribution 
by TEM/EDX. 
Universe, population and sample 
Universe: 
Patients: HH patients homozygous for the p.Cys282Tyr mutation of the HFE gene. 
Controls: Adult individuals without known pathology. 
Population: 
Patients: The population analysed in this study will be composed by HH patients homozygous for 
the p.Cys282Tyr mutation of the HFE gene regularly followed-up at the Haemochromatosis Clinic from 
HSA/CHP. A total of about 500 patients are registered and are regularly followed-up at the clinic, and 90 
of these are genetically characterized as HH homozygous for the p.Cys282Tyr mutation. 
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Controls: The control population for this project will be recruited among volunteer regular blood 
donors attending the HSA Blood Bank. 
Sample:  
Patients: The sample population will be composed by a group of 6 patients with HH homozygous 
for the p.Cys282Tyr mutation of the HFE gene. 
Controls: The sample population for this project will be composed by a group of 6 sex and age 
matched subjects, selected among the population of regular blood donors attending the HSA Blood Bank. 
Participant selection 
Participants will be selected in a non-probabilistic consecutive way (by convenience). 
Patients and blood donors will be consecutively recruited at the time of their regular consultation or 
volunteer blood donation, respectively. 
Eligibility criteria 
Inclusion criteria: 
To be followed at the Haemochromatosis Clinic, as a HH patient homozygous for the p.Cys282Tyr 
mutation of the HFE gene, or be a regular blood donor at the CHP-HAS Blood Bank. 
Have a scheduled (or unscheduled in the case of controls) consultation during the period of 
recruitment. 
Agree to participate in the project and sign informed consent.  
Exclusion criteria: 
Not fill in the inclusion criteria. 
Patients with clinical conditions known to influence total lymphocytes numbers (such as 
autoimmune or viral diseases). 
Controls whose donation is the first will be excluded. 
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Work plan 
Tasks associated to the project 
Task list 
During the execution of this project the following tasks are planned: 
 
Tasks description 
Task 1: Inform about the study and data collection from clinical files 
Duration: 2 months 
Expected date for 
start: 
14-09-2014 
Expected date for 
conclusion: 
31-10-2014 
Institutions, 
Departments and 
Services 
HSA/CHP – DM – SHC – Haemochromatosis clinic 
Description: 
During the period of consultation, the responsible for the Haemochromatosis 
Clinic (Graça Porto), will inform the patients about the study, requesting their 
participation. 
On days in which the supervisor (Margarida Lima) is responsible for the 
observation and selection of regular blood donors at the Blood Bank, she will 
inform them about the study, requesting their participation. All participants will 
receive a leaflet with most relevant information about the study. 
According to the participant recruitment, it will be collected the corresponding 
analytic data registered at the moment of diagnosis in their clinical files; in the 
next week, will be collected the results from the CBC and biochemical study, 
which is normally made after regular phlebotomies. The collection of controls´ 
data will be held under the same rules. The supervisor will overlook the process 
of data collection from clinical files. 
Researchers 
involved, roles and 
responsibilities 
Daniel Mendes – Data collection and registering. 
Graça Porto – Inform the patients about the study and supervise data collection 
and registering. 
Task 
number 
Task designation Beginning 
date 
Conclusion 
date 
1 Inform about the study and data collection from clinical files 14-09-2014 31-10-2014 
2 Blood sample collection 01-10-2014 31-01-2015 
3 Cell cycle studies 01-10-2014 31-01-2015 
4 Bleomycin genotoxicity tests 01-11-2014 31-02-2014 
5 TEM/EDX studies 01-02-2015 31-03-2015 
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Task 2: Blood sample collection 
Duration: 4 months 
Expected date for 
start: 
01-10-2014 
Expected date for 
conclusion: 
31-01-2015 
Institutions, 
Departments and 
Services 
HSA/CHP – DM – SHC – Haemochromatosis clinic and HSA Blood Bank 
Description: 
It will be carried out the collection of 2 blood samples (1 tube with EDTA-K3, 
with 4.5ml of blood; 1 tube with sodium heparin with 7.5 ml of blood); The 
procedure does not involve risks since it will be performed directly from the 
blood bag system without additional venous puncture. 
It will be collected at most 2 samples from each patient and 2 samples from 
each blood donors per week. 
The blood samples will be sent for processing to the CmL (Cytometry 
Laboratory) SHC-HSA-CHP, addressed to Técn. Sónia Fonseca. 
Researchers 
involved, roles and 
responsibilities 
Haemochromatosis Clinic: Nurse - Graça Melo will be in charge of collecting 
of blood samples from patients. 
HAS Blood Bank: Nurses (various) will be in charge of collecting samples 
from blood donors. 
 
 
 
 
 
Task 3: Cell cycle studies 
Duration: 4 months 
Expected date for start: 01-10-2014 
Expected date for 
conclusion: 
31-01-2015 
Institutions, Departments 
and Services 
HSA/CHP – DM – SHC – CmL 
Description: 
Using flow cytometry techniques, we aim to verify what percentage of T 
lymphocytes is distributed to the different phases of the cell cycle (S/G1 
and G2/M) in HH patients and controls. 
Researchers involved, 
roles and responsibilities 
Daniel Mendes – Cooperate with the performance of the technique and 
analysis of results. 
Sónia Fonseca - Flow cytometry studies (sample processing and data 
analysis) 
Margarida Lima – Supervising of the study and analysis of results. 
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Task 4: Bleomycin genotoxicity test 
Duration: 4 months 
Expected date for start: 01-11-2014 
Expected date for conclusion: 31-02-2015 
Institutions, Departments and 
Services 
ICBAS/UP – CgL 
Description: 
Perform BLM genotoxicity test in T lymphocytes of HH patients 
and controls. 
Researchers involved, roles and 
responsibilities 
Daniel Mendes – Cooperate with the performance of the 
technique and analysis of results. 
Rosa Sousa – Cytogenetic studies (sample processing and data 
analysis) 
Beatriz Porto – Supervising of the study and analysis of results. 
 
 
 
 
 
Task 5: TEM/EDX studies 
Duration: 2 months 
Expected date for start: 01-02-2015 
Expected date for conclusion: 31-03-2015 
Institutions, Departments and 
Services 
IBMC/UP – HEMS 
Description: 
Perform TEM/EDX studies in selected T lymphocytes of HH 
patients and controls. 
Researchers involved, roles and 
responsibilities 
Daniel Mendes – Cooperate with the performance of the 
technique and analysis of results. 
Rui Fernandes – Perform the technique and interpret the results. 
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Material and Methods 
Sample collection 
Blood samples will be obtained at the time of the patients and controls regular visits to the 
Haemochromatosis clinic and blood bank respectively. Peripheral blood will be collected as an additional 
sample from the phlebotomy device with no need for an additional venipuncture in HH patients. In the 
same way, no additional venipuncture will be necessary to collect the samples from controls. It is expected 
that at the time of the visit, routine measurements of biochemical parameters of iron metabolism (serum 
iron, serum transferrin, transferrin saturation and serum ferritin) and CBC will be obtained from HH 
patients. At the time of collection, the participants will be informed about the study and asked to give their 
Informed Consent. 
Samples for cell cycle studies and bleomycin genotoxicity tests will be collected into K3-ethylene-
diamine-tetracetic acid (EDTA-K3)-containing tubes. Overall, about 12 ml of blood will be collected from 
each participant for the purpose of the study. 
Technical procedures 
Flow Cytometry 
Flow cytometry is a standard laboratory tool in the identification of lymphocyte populations and 
subpopulations, a method referred to as immunophenotyping. The clinical application of this technology 
has been facilitated by the development of instruments and data analysis systems suitable for routine use in 
diagnostic laboratories. Flow cytometry allows evaluate what percentages of cells are in a particular phase 
of the cell cycle, using DNA measurement technology. It is this last function that will be used in our study. 
Bleomycin Genotoxicity test 
BLM acts breaking DNA double helix by the production of free radicals. When it chelates with iron 
in the presence of oxygen to form a bleomycin-Fe2+ complex, single-strand and double-strand DNA breaks 
are induced and lipid peroxidation is mediated by the production of free radicals. Therefore, this iron-
dependent process allows to quantifying, indirectly, iron uptake in T lymphocytes, by evaluation of 
chromosome instability (CI) through cytogenetic methods. 
TEM/EDX 
Transmission electron microscopy (TEM) will give us a picture of the cellular ultrastructure which 
will allow us to know where we could find iron oxide nanoparticles in intracellular different compartments. 
Subsequently, the Energy-dispersive X-ray spectroscopy (EDX) technology will allow us elemental 
characterization of the nanoparticles within the cell. The scientific basis relies on the fact that the interaction 
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of some source of X-ray excitation with different molecular components of the sample will produce a 
unique set of peaks according to the chemical composition. 
Theoretical bases 
Flow Cytometry 
The DNA measurement and cell cycle studies will be performed by flow cytometry, based upon the 
ability of propidium iodide (PI) to bind stoichiometrically to double strand DNA under appropriate staining 
conditions. Cells stained in this manner will emit red fluorescence in direct proportion to their DNA content 
and based on this parameter the percentage of cells in G0+G1 (DNA content = n), S and G2+M (DNA 
content = 2n) phases of the cell cycle will be evaluated. In order to determine the DNA content in specific 
lymphocyte populations, blood cells will be stained for cell surface molecules prior to DNA staining with 
PI. This will be done by staining cells with a FITC-conjugated mouse anti-human CD3 Mab (green 
fluorescence), following by staining with a FITC-conjugated rabbit anti-mouse IgG polyclonal antibody 
(Ab). 
Bleomycin Genotoxicity test 
BLM is a glycopeptide antibiotic with anticancer properties produced by Streptomyces verticillus. 
One of its mechanisms of action is breaking the DNA double helix by the production of free radicals, a 
process that is oxygen and iron dependent. High concentrations of BLM arrest cells in the G0/G1 phase of 
cell cycle, leading to cell death and lower concentrations of BLM induce over-replication. This molecule 
can be used in an assay for measuring iron concentration in cells. BLM reacts with NTBI forming BLM-
iron complex which releases reactive hydroxyl radical (OH⋅) and promotes DNA damage.  NTBI 
concentrations increase with the amount of iron, however some molecular defence mechanisms against this 
type of iron can reduce iron mediated BLM genotoxicity, independently of cell iron concentrations. 
TEM/EDX  
Transmission electron microscopy (TEM) is a microscopy technique which allows to known the 
ultrastructure of a cell or a cluster of cells. It utilizes a beam of electrons that passes through an ultra-thin 
specimen, forming an image in consequence of the interaction of the electrons with the atoms of the cells. 
Subsequently, the image is decoded by an imaging device. Simultaneously with the TEM, we can use 
Energy-dispersive X-ray spectroscopy (EDX), in order to perform elemental analysis and chemical 
characterization of a sample. The scientific basis relies on the fact that the interaction of some source of X-
ray excitation with different molecular components of the sample will produce a unique set of peaks 
according to the chemical composition. 
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Methods 
Flow Cytometry 
The blood sample will be submitted to cell surface immunophenotyping with FITC-conjugated 
mouse anti-CD3 Mab (IgG) followed by staining with FITC conjugated rabbit anti-mouse IgG polyclonal 
Ab and basic cellular DNA measurement based on flow cytometry techniques, using the COULTER DNA 
PREP Reagents KitTM, according to a protocol that was described in detail (Lima M et al, 2000). This 
reagent kit contains non-ionic detergents to permeabilizing cells (DNA PREP LPR reagent), PI (to stain 
double strain nucleic acids, DNA and dsRNA) and RNAse (to destroy RNA) (DNA PREP Stain reagent). 
After staining, samples will be acquired in a flow cytometer (Navios, BC) using the System IITM software 
Beckman Coulter (BC). 
Bleomycin Genotoxicity test 
Peripheral blood cultures are set up in RPMI 1640 (Sigma) complete medium supplemented with 
15% FCS (Gibco), antibiotics (10,000 units/ml of penicillin and 10,000 μg/ml of streptomycin) (Gibco) 
and 29 mg/ml of L-glutamine (Sigma). Cultures are stimulated with 5 μg/ml of phytohaemagglutinin 
(Gibco) and placed in an incubator at 37°C with 5% CO2 atmosphere, for 72 h.  
BLM is added 24h after the initiation of cell culture at the final concentration of 3,33 µg/ml. At 72 
hours of culture, cells are harvested after a 1h incubation with 100 μl colcemid® (Gibco) followed by 
hypotonic treatment with 75 mM KCL during 15 minutes and fixation in 1:3 solution of acetic acid: 
methanol. Chromosome preparations are made by the air drying method. 
For the already fixed cells, the resulting suspensions are dropped onto microscope slides and left to 
dry. These slides are then exposed to 4% Giemsa solution stain, made in PBS, for 5 minutes and then rinsed 
in distilled water. Cytogenetic analysis is performed on coded slides. To avoid bias in cell selection, 
consecutive metaphases, which appear intact with sufficient well-defined chromosome morphology, are 
selected for the study. Each cell is scored for chromosome number and structural abnormalities. As CI 
parameters, percentage of aberrant cells and nº of breaks per cell are used. 
TEM/EDX 
T lymphocytes will be incubated with 5 mM of Venofer® (5:100) for up to 3 hours, washed and 
iron cellular localization analysed by autometallography (EDX technology) coupled with transmission 
electron microscopy (TEM). Briefly, following each period of incubation with sucrose coated iron oxide 
nanoparticles, T lymphocytes will be washed with washing buffer and fixed with 2% glutaraldehyde (in 0.1 
M Na- cacodylate+0.1 M sucrose, pH 7.2). Cells will then be submitted to sulfidation with 1% ammonium 
sulphide (pH 9.0) in 70% (v/v) ethanol, for 15 minutes. After three washes in water, cells will be incubated 
in a colloidprotected developer containing gum arabic, citrate buffer (pH 3.8), hydroquinone and silver 
The effect of iron oxide nanoparticles on T lymphocytes 
Daniel Mendes, ICBAS/UP – 2013/2014 and 2014/2015 
 
21 
nitrate, for 25 minutes in the dark. For transmission electron microscopy, cells will be washed in 50 mM 
sodium cacodylate (pH 7.4), incubated for 24 h in 1% OsO4 (prepared in 10 mM calcium chloride) and 
then in 1% uranyl acetate for 1 h. Following ethanol dehydration and Epon embedding, ultrathin sections 
will be obtained and analyzed with a Jeol 1400 (60 kV) microscope equipped with an Orious 1100W CCD 
digital camera. 
Equipment 
Equipment Type Brand Model Place 
Automated hematologic 
counter 
Coulter LH780 Cytometry Laboratory of SHC/CHP 
Flow cytometer Coulter Navios Cytometry Laboratory of SHC/CHP 
Refrigerators   Cytometry Laboratory of SHC/CHP 
Centrifuges   Cytometry Laboratory of SHC/CHP 
Automated Micropipetes   Cytometry Laboratory of SHC/CHP 
Hardware: Computers and 
Printers 
  Cytometry Laboratory of SHC/CHP 
Software: Multicycle AV 
for Windows™ (DNA Cell 
Cycle Analysis Software) 
Phoenix  Cytometry Laboratory of SHC/CHP 
Jeol 1400 (60 kV) 
microscope 
  HEMS of IBMC 
Centrifugue Beckman GP Cytogenetics Laboratory at ICBAS/UP 
Fume hood Cruma 990 G-F Cytogenetics Laboratory at ICBAS/UP 
Incubator Nuaire NU4500 Cytogenetics Laboratory at ICBAS/UP 
Laminar Flow Hood 
Gelaire 
Flow 
Laboratories 
BSB 4A Cytogenetics Laboratory at ICBAS/UP 
Microscope Olympus CX31RBSF Cytogenetics Laboratory at ICBAS/UP 
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Reagents 
Reagent finality Description Manufacturer Refernce Provider 
Sample collection EDTA (K3) BDB - Enzifarma 
Flow 
cytometry 
studies 
Cell 
preparation 
(washing 
and 
suspension) 
Phosphate Buffer Saline 
(PBS) buffer 
BC 6603369 IZASA 
Cell cycle 
studies 
DNAprepTM reagent system BC 6607055 IZASA 
Mouse anti-human CD3 
FITC 
BC-IOT A07746 IZASA 
Rabbit anti-mouse IgG FITC DK F0232 Lusopalex 
TEM/EDX analysis 
Washing buffer    
Glutaraldehyde    
Ammonium sulphide    
Colloidprotected developer 
containing gum arabic 
   
Citrate buffer    
Hydroquinone    
Silver nitrate    
Cacodylate    
OsO4    
Uranyl acetate    
Bleomycin Genotoxicity 
tests 
Acetic acid (97%) Merck 1000621011 VWR 
Bleomycin TEVA 110000338 HSA 
Colcemid Gibco 15212-012 Alfagene 
Fetal Bovine Serum (FBS) Sigma F6179 Sigma 
Hydrochloric acid (HCl, 37%) Merck 1.003.171.000 VWR 
Giemsa Merck 1092040500 VWR 
KCl Sigma P4504 Sigma 
L-Glutamine Sigma G8540 Sigma 
The effect of iron oxide nanoparticles on T lymphocytes 
Daniel Mendes, ICBAS/UP – 2013/2014 and 2014/2015 
 
23 
 
Consumable material  
Polypropylene tubes (7 mL); Pasteur pipettes; sterile pipettes 5ml, 10ml, 20ml; Pipette tips; slides; 
gloves; 
Data analysis 
Flow cytometry data analysis: Stored listmode data will be analysed using specific software for 
DNA analysis “Multicyle AV for Windows™ - DNA Cell Cycle Analysis Software” (Phoenix Flow 
System, PFS). Using this software, the percentage of T lymphocytes in each phase of the cell cycle (G0+G1, 
S and G2M) will be calculated. 
Association studies between T lymphocytes numbers and the corresponding phenotypic profile (%S 
and G2/M cells and % of apoptotic cells) will be performed. Data will be further correlated with the other 
clinical parameters (CBC and biochemical).  
Cytogenetic data analysis: Chromosomes are observed in dividing cells during metaphase, when 
chromosomes are more condensed. For the purpose of CI analysis, the method routinely used in cytogenetic 
laboratories is based on peripheral blood cultures. Cells at this stage are the ones meticulously analysed by 
the scorer, who will then check for unusual chromosomal morphology and/or chromosome count indicative 
of CI. 
Every data will be analysed with the support of statistic software (SPSS and/or Statgraphics). 
Methanol Merck 1.060.091.011 VWR 
Penicillin-Streptomycin Gibco 15140-148 Alfagene 
Phytohaemagglutinin (PHA) Gibco 10576-015 Alfagene 
RPMI 1640 Sigma R0883 Sigma 
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Calendarization 
Duration 
Global: 22 months.   Planning: 9 months.  Execution: 11 months. 
Start and end dates 
Global: October 2013 to July 2015    Execution: September 2014 to July 2015 
Global chronogram of activities 
 ACADEMIC YEAR 2013/2014 ACADEMIC YEAR 2014/2015 
Month 10 11 12 01 02 03 04 05 06 07 08 09 10 11 12 01 02 03 04 05 06 07 
Choice of the work area                       
Integration on research 
team 
                      
Choice of theme and 
subject 
                      
Identification of 
problems/issues 
                      
Formulation of the 
questions 
                      
Delineation of the 
hypothesis 
                      
Definition of the aims                       
Review / study design                       
Study conception                       
Preparation of project 
proposal 
                      
Submission for approval                       
Presentation of the 
proposal 
                      
Project implementation                       
Sample collection and 
analytical procedures 
                      
Analysis and 
interpretation of results 
                      
Report writing                       
Presentation of the 
results 
                      
MIM dissertation                       
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Project execution chronogram  
Year 2014 2015 
Task 09 10 11 12 01 02 03 04 05 
1          
2          
3          
4          
5          
Goals to be achieved (milestones) 
 Study started: September 1th,  2014 
 Data collected and entered in a computer file: March 31th, 2015 
 Data processed, analysed and interpreted: May 31th, 2015 
 Implementation / presentation  report of results: June 12th, 2015 
Deliveries to be made (deliverables) 
Delivery of the project proposal: May 31th, 2014 
Delivery of execution/presenting results report: June 12th, 2015 
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Output indicators 
Oral communications and posters 
 Oral presentation of the proposal at the 6th Jornadas de Iniciação á Investigação Clínica (JIIC) (June / 
July 2014) 
 Oral presentation of the results at the 7th JIIC (June / July 2015) 
 Presentation of the results in poster in scientific meeting for haematology specialists (2014) – Annual 
meeting of Portuguese Society of Haematology. 
 Presentation of the results in poster in an international scientific meeting of the specialty (2015) – 
European Iron Club Meeting 
Manuscripts 
 Research Project proposal (2014) 
 Thesis defence (2015) 
 Article for publication in national or international medical journal with referees (2015) 
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Participant information and informed consent 
Informed consent to use the blood as a contribution for research will be obtained at the time of 
collection. Furthermore samples will be processed in accordance with all the established rules of privacy 
and confidentiality as define in the Helsinki Declaration. For participants that eventually manifest an 
interest in being better informed about the study, an information sheet (attached) will be available and 
provided at the Haematology Service. Although it is planned to hold cell cycle tests, none of these is a 
genetic test. 
Blood samples for the research purposes will be treated as volunteer donations with some 
conditions: in order to assure the “gift relationship” between the donor and the researcher, the formal 
responsibility for custodianship of the samples collected at the HSA Blood Bank or at the 
Haemochromatosis Clinic will be transferred to the Cytometry Laboratory (CHP-HAS), Cytogenetics 
Laboratory (ICBAS), or the BCRIB Laboratory at IBMC.  
Informed consent of patients with Hereditary Haemochromatosis and blood donors will be request 
and obtained based on brief explanation of the study and posterior explanations appeal by patients. The 
model of informed consent is available in annex. 
Other issues with ethical implications  
Risks and benefits 
There are no risks associated with participation in the study. No additional punctures will be needed. 
Overall benefit is due to the improving the understanding of cellular effects of use iron oxide nanoparticles 
formulations in clinical practice. 
There are no direct benefits to participants. The benefits are indirect and based on possible 
improvements of clinical knowledge that may result from the study. 
Confidentiality and anonymisation 
Confidentiality of data is guaranteed. 
The collection of data from clinical cases will be taken by the student, with the supervision of the 
Supervisor. 
The information recorded for research purposes (demographic, clinical and analytical data) will be 
anonymised. 
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Budget 
 
 Estimated value (€) 
Reagents and consumables * please see next table 1950.00 
Administrative material (photocopies, paper sheets, etc.) 30.00 
Acquisition services (TEM/EDX) 480.00 
Poster printing for results presentation 50.00 
Student enrollment in Portuguese medical congress (Annual Meeting of the 
Portuguese Society of Hematology) 
200.00 
Student enrollment in international congress (European Iron Club Meeting) 1200.00 
Jornadas de Iniciação à Investigação Clínica (organization) 50.00 
TOTAL €3960.00 
 
 
Reagents and consumables 
Purpose Designation Price per unit (€) 
Number of 
units 
Price (€) 
without IVA 
Subtotal 
(€) 
Flow cytometry 
(reagents) 
Anti-CD3 500.00 1 500.00 
1700.00 
Coulter 
DNAprepTM 
reagent system 
1200.00 1 1200.00 
Genotoxicity tests 
with Bleomycin 
 
00.00 
 
1 
150.00 
 
150.00 
Material  100.00 1 100.00 150.00 
TOTAL sem IVA 1540.00 
TOTAL com IVA (XX%) 1950.00 
Financing: 
The study will be funded by ICBAS / UP, through a grant given to DIIC. 
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Abbreviations and acronyms 
BCRIB, Basic and Clinical Research on Iron Biology, 
BLM, Bleomycin 
CHP, Centro Hospitalar do Porto 
CgL, Cytogenetics Laboratory  
CI, Chromosome Instability 
CmL, Cytometry Laboratory  
DIIC, Disciplina de Iniciação à Investigação Clínica  
DM, Department of Medicine 
DMT1, Divalent Metal Transporter 1 
DNA, Deoxyribonucleic acid 
EDX, Energy-Dispersive X-ray spectroscopy 
EM, Electron Microscopy 
HEMS, Histology and Electron Microscopy Service 
HH, Hereditary Haemochromatosis  
HSA, Hospital de Santo António 
IBMC, Institute for Molecular and Cell Biology 
ICBAS, Abel Salazar Institute of Biomedical Sciences 
JIIC, Jornadas de Iniciação à Investigação Clínica 
MRI, Magnetic Resonance Imaging 
NTBI, Non-transferrin-bound serum iron 
PI, Propidium Iodide 
SHC, Clinical Haematology Service  
TEM, Transmission electron microscopy 
TfR1, Transferrin receptor 1 
UP, University of Porto  
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List of attachments 
 Folha de rosto do estudo de investigação 
 
 Pedidos de autorização institucional  
 
 Termos de responsabilidade 
 
 Termos de autorização local 
 
 Termo de consentimento informado  
 
 Folheto informativo para os participantes 
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TRABALHOS ACADÉMICOS DE INVESTIGAÇÃO (que conferem grau) 
 
 
Data de entrega 
(ou NA, não aplicável) 
Secretariado 
(Assinatura) 
 
Documentos comprovativos 
 
Inscrição em Licenciatura, Mestrado ou Doutoramento NA  
 
Cartas do Aluno, a solicitar autorização institucional 
Presidente do Conselho de Administração   
Presidente da CES   
Diretor do DEFI   
Termos de responsabilidade de Alunos e Orientadores 
Aluno   
Orientador do Projeto   
Supervisor do Projeto, Docente responsável pela DIIC   
Termos de autorização local (no CHP) 
Responsáveis por Unidades / Gabinetes / Setores*   
Diretores de Serviço   
Diretores / Conselhos de Gestão de Departamentos   
 
Proposta 
 
Folha de Rosto do Estudo de Investigação (modelo próprio)   
Proposta de Trabalho Académico de Investigação   
 
Anexos 
 
Curriculum Vitae do Aluno  NA  
Termo de Consentimento Informado   
Folheto com informação para dar aos Participantes   
Carta a solicitar dispensa de Consentimento Informado* NA  
Inquéritos / questionários ou guiões de entrevistas* NA  
Formulário para recolha de dados dos processos clínicos* NA  
Outros documentos* NA  
 
* Se aplicável. 
SECRETARIADO: Data de conclusão da entrega de documentação 
 
 
        Data       Assinatura 
___/___/_____   _________________________ 
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Folha de rosto do estudo de investigação 
TÍTULO 
O EFEITO DE NANOPARTICULAS DE ÓXIDO DE FERRO EM LINFÓCITOS T 
CLASSIFICAÇÃO 
Trabalho Académico de Investigação X (Mestrado Integrado em Medicina) 
Projecto de Investigação  X 
Investigação básica laboratorial X   
VERSÃO 
Novo X    
CALENDARIZAÇÃO 
Data início: Outubro de 2013 Data conclusão: Julho de 2015 Prazo a cumprir: Julho de 2014 
ALUNOS E ORIENTADORES 
Aluno  
DANIEL AZEVEDO MENDES; ICBAS – UP; MIM; 5ºANO; daniel5.mds@gmail.com; 919651201 
Orientador do projeto  
PROFª. DOUTORA GRAÇA PORTO; MÉDICA, IMUNOHEMOTERAPEUTA; CHEFE DE 
SERVIÇO, SHC DO HSA/CHP; PROFESSORA CATEDRÁTICA, ICBAS/UP; gporto@ibmc.up.pt; 
968345652.  
Supervisor do projeto / Responsável pela DIIC  
PROFª. DOUTORA MARGARIDA LIMA; MÉDICA, IMUNOHEMOTERAPEUTA; 
ASSISTENTE HOSPITALAR GRADUADA, SHC DO HSA/CHP; PROFESSORA CONVIDADA, 
ICBAS/UP; margaridalima@chporto.min-saude.pt; 966 327 115 
OUTROS INVESTIGADORES 
Investigadores 
PROFª BEATRIZ PORTO, PROFESSORA AUXILIAR E INVESTIGADORA NO 
LABORATÓRIO DE CITOGENÉTICA DO ICBAS/UP; bporto@icbas.up.pt; 220428253  
PROMOTOR O próprio X 
INSTITUIÇÕES E SERVIÇOS 
 Unidades, Departamentos e Serviço do CHP 
HSA/CHP – DM – SHC 
Outras Instituições intervenientes 
IBMC/UP 
ICBAS/UP 
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CARATERÍSTICAS do estudo (Assinale as opções corretas) 
Alvo do estudo      Países / Instituições envolvidos 
Humanos x       Nacional X  Institucional X 
Natureza do estudo     Caraterísticas do estudo (desenho) 
Clínico X Laboratorial X    AnalíticoX  Observacional X
        Transversal X 
Participantes  
Existência de grupo controlo: Sim X 
Seleção dos Participantes: Não aleatória X 
Estudos observacionais:   
Tipo: Casos-controlos X 
Estudos experimentais: 
Não se aplica 
Outros aspetos relevantes para a apreciação do estudo: 
Participação de grupos vulneráveis  Não X 
Convocação de doentes / participantes   Não X 
Consentimento informado  Sim X     
Inquéritos / questionários   Não X 
Entrevistas   Não X 
Colheita de produtos biológicos  Sim X  (No CHP, Não anonimizados) 
Armazenamento de produtos biológicos Não X 
Criação de bancos de produtos biológicos  Não X 
Realização de exames / análises  Sim X  (No CHP, ICBAS e IBMC)  
Realização de estudos genéticos  Não X 
Recolha de dados  Sim X  (Dados: clínicos, laboratoriais: e analíticos) 
Criação de bases de dados  Não X 
Saída para outras instituições  Não X 
ORÇAMENTO E FINANCIAMENTO 
Orçamento total: ________ Euros Contrato financeiro em anexo: Não □    Sim □ 
Financiamento: Interno (CHP)  ________ Euros  Externo (Outros) _______ 
Euros 
Entidades financiadoras: ______________________________________________________ 
INDICADORES  
Dissertação Mestrado Integrado em Medicina 
Data:     Assinatura do proponente (Aluno): 
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Pedidos de autorização institucional 
Trabalho académico de investigação: 
O efeito de nanoparticulas de óxido de ferro em linfócitos T 
Aluno da DIIC do curso de MIM do ICBAS/UP e do CHP:  
Daniel Azevedo Mendes 
Presidente do Conselho de Administração do CHP 
Exmo. Senhor Presidente do Conselho de Administração do CHP 
Daniel Azevedo Mendes, na qualidade de Aluno, vem por este meio, solicitar a Vossa Exa. autorização 
para realizar no Centro Hospitalar do Porto o Estudo de Investigação acima mencionado, de acordo com 
o programa de trabalhos e os meios apresentados. 
        Data       Assinatura 
___/___/_____   _________________________ 
 
Presidente da Comissão de Ética para a Saúde do CHP 
Exma. Senhora Presidente da Comissão de Ética para a Saúde do CHP 
Daniel Azevedo Mendes, na qualidade de Aluno, vem por este meio, solicitar a Vossa Exa. autorização 
para realizar no Centro Hospitalar do Porto o Estudo de Investigação acima mencionado, de acordo com 
o programa de trabalhos e os meios apresentados. 
        Data       Assinatura 
___/___/_____   _________________________ 
 
Diretora do Departamento de Ensino, Formação e Investigação do CHP 
Exma. Senhora Diretora do Departamento de Ensino, Formação e Investigação do CHP 
Daniel Azevedo Mendes, na qualidade de Aluno, vem por este meio, solicitar a Vossa Exa. autorização 
para realizar no Centro Hospitalar do Porto o Estudo de Investigação acima mencionado, de acordo com 
o programa de trabalhos e os meios apresentados. 
        Data       Assinatura 
___/___/_____   _________________________ 
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Termos de responsabilidade 
Trabalho académico de investigação: 
O efeito de nanoparticulas de óxido de ferro em linfócitos T 
Aluno da DIIC do curso de MIM do ICBAS/UP e do CHP:  
Daniel Azevedo Mendes 
Aluno 
Na qualidade de Aluno, comprometo-me a executar o Trabalho Académico de Investigação 
acima mencionado, de acordo com o programa de trabalhos e os meios apresentados, respeitando os 
princípios éticos e deontológicos e as normas internas da instituição. 
Aluno        Data   Assinatura 
__________________________________________ ___/___/___ _________________ 
Orientador do projeto 
Na qualidade de Orientador, solicito autorização do Conselho de Administração para que o 
Aluno acima referido possa desenvolver no CHP o seu Trabalho de Investigação. Informo que me 
comprometo a prestar a orientação necessária para uma boa execução do mesmo e a acompanhar o 
Aluno nas diferentes fases da sua realização, de acordo com o programa de trabalhos e meios 
apresentados, bem como por zelar pelo respeito dos princípios éticos e deontológicos e pelo 
cumprimento das normas internas da instituição. 
Nome        Data   Assinatura 
_________________________________________  ___/___/___ ____________________ 
Instituição   Departamento     Serviço / Setor 
_________________  ________________________ __________________________ 
Supervisor do projeto / Responsável pela DIIC 
Na qualidade de Docente Responsável pela DIIC / Supervisor do Aluno no CHP, 
comprometo-me a prestar a orientação necessária para uma boa execução do Trabalho de 
Investigação, de acordo com o programa de trabalhos e meios apresentados. Mais declaro que 
acompanharei o Aluno, responsabilizando-me por supervisionar a execução do trabalho no CHP, bem 
como por zelar pelo respeito dos princípios éticos e deontológicos e pelo cumprimento das normas 
internas da instituição. 
Nome      Data    Assinatura 
Margarida Lima    ___/___/___   __________________ 
Departamento: DEFI 
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Termos de autorização local 
Trabalho académico de investigação: 
O efeito de nanoparticulas de óxido de ferro em linfócitos T 
Aluno da DIIC do curso de MIM do ICBAS/UP e do CHP:  
Daniel Azevedo Mendes 
Diretores de Serviço 
Na qualidade de Diretor de Serviço, declaro que autorizo a execução do Estudo de 
Investigação acima mencionado e comprometo-me a prestar as condições necessárias para a boa 
execução do mesmo, de acordo com o programa de trabalhos e os meios apresentados. 
Serviço    Nome do Diretor  Data   Assinatura 
_____________________________ ____________________ ___/___/___ _______________ 
_____________________________ ____________________ ___/___/___  _______________ 
_____________________________ ____________________ ___/___/___ _______________ 
Diretores / Conselhos de Gestão de Departamento 
Na qualidade de Diretor do Departamento, declaro que autorizo a execução do Estudo de 
Investigação acima mencionado e comprometo-me a prestar as condições necessárias para a boa 
execução do mesmo, de acordo com o programa de trabalhos e os meios apresentados. 
Departamento    Nome do Diretor  Data   Assinatura 
_____________________________ ____________________ ___/___/___ _______________ 
_____________________________ ____________________ ___/___/___ _______________ 
_____________________________ ____________________ ___/___/___ _______________ 
Responsáveis por Unidades, Gabinetes ou Setores (se aplicável) 
Na qualidade de Responsável pela Unidade / Gabinete / Setor, dou parecer favorável à 
execução do Estudo de Investigação acima mencionado e comprometo-me a prestar as condições 
necessárias para a boa execução do mesmo, de acordo com o programa de trabalhos e os meios 
apresentados. 
Unidade / Gabinete / Setor  Nome do Responsável Data   Assinatura 
_____________________________ ____________________ ___/___/___ _______________ 
_____________________________ ____________________ ___/___/___ _______________ 
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Termo de consentimento informado 
O EFEITO DE NANOPARTICULAS DE ÓXIDO DE FERRO EM 
LINFÓCITOS T 
Eu, abaixo-assinado__________________________________________________________: 
Fui informado de que o Estudo de Investigação acima mencionado se destina a clarificar os efeitos 
da formulação de ferro endovenoso Venofer®, frequentemente utilizada na clínica médica, em 
determinadas células do sangue. Os linfócitos T serão o alvo deste estudo e dizem respeito a células 
de defesa do sistema imunitário presentes no sangue em grande quantidade, que podem ser obtidas 
facilmente através de uma punção venosa com colheita de sangue periférico. Por sua vez, o Venofer® 
é uma formulação utilizada com grande frequência na correção de estados de depleção de ferro que 
conduzem grande parte das vezes a estados de anemia. O ferro presente nesta formulação encontra-
se sob a forma de nanopartículas de óxido de ferro que uma vez administradas podem ser rapidamente 
utilizadas pelo organismo. Este estudo visa identificar alguns dos efeitos desencadeados por estas 
partículas nos linfócitos T. 
Sei que neste estudo está prevista a realização de colheitas de sangue periférico tendo-me sido 
explicado em que consistem e quais os seus possíveis efeitos.  
Sei que alguns exames não podem ser efetuados neste hospital e que, por isso, têm que ser realizadas 
noutras instituições, como o Instituto de Ciências Biomédicas Abel Salazar (ICBAS) e o Instituto 
de Biologia Molecular e Celular (IBMC). 
Foi-me garantido que todos os dados relativos à identificação dos participantes neste estudo são 
confidenciais e que será mantido o anonimato.  
Sei que posso recusar-me a participar ou interromper a qualquer momento a participação no estudo, 
sem nenhum tipo de penalização por este facto. 
Compreendi a informação que me foi dada, tive oportunidade de fazer perguntas e as minhas dúvidas 
foram esclarecidas. 
Aceito participar de livre vontade no estudo acima mencionado. 
Concordo que sejam efetuados os exames e a colheita de amostras de sangue para realizar as análises 
que fazem parte deste estudo. 
Também autorizo a divulgação dos resultados obtidos no meio científico, garantindo o anonimato. 
 
Nome do Participante no estudo. 
Data      Assinatura 
      ___/___/_____   _________________________________________  
 
 
Nome do Investigador Responsável 
Data      Assinatura 
      ___/___/_____   ________________________________________ 
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Folheto informativo para os participantes 
 
 
(formato A5) 
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The project described above was approved by the ethics committee of Centro Hospitalar do 
Porto – Hospital de Santo Antonio (CHP-HSA). It was executed between September 1th, 2014 and 
May 15th, 2015.  
The aim of the project was to observe the in vitro effect of iron oxide nanoparticles, commonly 
used in the clinical treatments, on T Lymphocytes and to compare that effect between patients with 
Hereditary Haemochromatosis (HH), homozygous for the p.Cys282Tyr HFE mutation and normal 
healthy controls. To reach this goal various parameters of the cell cycle, apoptosis and 
immunophenotype were evaluated by flow cytometry. The effect of these particles was also evaluated 
on chromosome instability and on bleomycin induced genotoxicity using cytogenetic studies. 
Sample collection occurred at the Haemochromatosis Clinic and the execution of the 
Cytometry experiments took place at the Cytometry Laboratory of CHP-HSA, both belonging to the 
Clinical Haematology Service. Cytogenetic experiments were executed on the Laboratory of 
Cytogenetics, Department of Microscopy of Abel Salazar Institute of Biomedical Sciences (ICBAS), 
and University of Porto (UP). The project execution had the collaboration of all participants 
mentioned above. 
This report aims to describe the population studied, the procedures performed, the results 
obtained and conclusions driven. The background and objectives of the project were described in 
detail in the project proposal. 
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CHANGES TO THE ORIGINAL PROJECT PROPOSAL 
 
• In order to perform all the experiments included in the project proposal it was 
necessary to collect four heparin tubes (6ml) and 1 EDTA tube (4ml) making a total of 28ml of blood 
per person.  To avoid potential complications related to inconvenience and discomfort during the 
blood donation procedure or eventually related to vascular volume reduction, we decided not to use 
the CHP blood donors as controls. As an alternative approach, voluntary healthy persons of the same 
gender and age group of patients, recruited among laboratory workers or acquaintances were used as 
controls. In all cases, informed consent was obtained before sample collection. 
 
• Because of its relevance in the interpretation of cytogenetic results, we decided to 
include studies of T cell apoptosis, which was not included in the initial project proposal. The 
materials and methodology are described in this execution report. 
 
• The beginning of tasks 2, 3, and 4, “Blood sample collection”, “Cell cycle studies” and 
“Bleomycin genotoxicity test”, respectively, have been delayed by approximately 2 months in 
consequence of the deferral by ICBAS/UP to provide some necessary reagents required to the 
preparation of apoptosis studies. 
 
• As a consequence of the above mentioned delay, analysis and interpretation of results 
have also been deferred and therefore it was not possible to submit the presentation of the results to 
the National Haematology Congress. In addition, due to previously unforeseen reasons, the meeting 
of the European Iron Club was postponed to April 2016.  
 
• Because of lack of financial support, transmission electron microscopy (TEM)/ 
energy-dispersive X-ray spectroscopy (EDX) experiments were not performed. This is still a goal to 
achieve in future.  
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DESIGN AND METHODS 
Controls 
The controls consisted of six subjects recruited (see above) according to gender and age matching 
with the patients. In order to obtain a homogeneous population in terms of iron parameters, the study 
sample included only males.  The age ranged from 42 to 68 years (average  standard deviation = 57 
 10). They had no known disease or clinical condition, therefore they were assumed as normal 
healthy subjects without performing any additional biochemical screening or other diagnostic test. 
Informed consent was obtained according to ethics committee of CHP approval.  
 A summary characterization of the control population in terms of total lymphocyte counts and 
T lymphocyte subpopulations is given in Table 1.  
 
Table 1.  Sample characterization – Controls. 
  Lymphocytes  Iron parameters 
Individuals Age Lymphocytes 
(x103/L) 
CD4+ 
(x103/L) 
CD8+ 
(x103/L) 
 
 1 57 1.77 1.02 0.31  
Not assessed 
 
2 68 2.38 0.93 0.27  
3 46 2.32 1.14 0.65  
4 58 2.34 1.61 0.28  
5 65 1.28 0.46 0.23  
6 42 1.45 0.55 0.33  
 
Patients 
Six HH patients were included in this study. All patients had an established diagnosis of HH 
and were regularly followed at Haemochromatosis Clinic where all the relevant clinical information 
was documented. As already mentioned, all patients had confirmation of genetic diagnosis of 
p.Cys282Tyr homozygous mutation. Patients were consecutively recruited at the time of their regular 
visit to the clinic and blood samples collected during the regular phlebotomy procedure. As mentioned 
above, only male patients were used. Their age ranged from 40 to 69 years (average  standard 
deviation = 53  13). For each patient the informed consent was obtained before collecting blood 
samples as explained in the project proposal approved by ethics committee of CHP.  
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A summary characterization of the patient population including total lymphocyte counts, T 
lymphocyte subpopulations and iron parameters at the time of the study is given in Table 2. 
 
Table 2. Sample characterization – Patients with Hereditary Haemochromatosis.  
  Lymphocytes  Iron parameters 
Individuals Age Lymphocytes 
(x103/L) 
CD4+ 
(x103/L) 
CD8+ 
(x103/L) 
 S.Iron 
(g/dL) 
SatT 
(%) 
S.Ferr 
(g/dL) 
1 69 1.67 1.03 0.26  184 55 162 
2 69 1.72 0.73 0.59  215 87 107 
3 40 3.10 1.65 0.60  236 74 128 
4 45 2.35 0.72 0.85  254 85 1697 
5 49 2.21 1.13 0.13  184 85 109 
6 43 1.09 0.48 0.18  165 53 166 
 
Abbreviations: S.Iron: serum iron; SatT: transferrin iron saturation; S.Ferr: serum ferritin. 
 
Sample collection 
To minimize any patient distress, peripheral venous blood samples were obtained from the 
phlebotomy bag device, at the time of the patient regular visit to the Haemochromatosis Clinic for 
their regular phlebotomy treatment. At the same time, recruited controls were invited to come to the 
treatment room where the same nurse collected blood by antecubital venipuncture. For each patient 
and each control 4 blood samples were collected in tubes of 6mL with sodium heparin to use for 
apoptosis studies and cell cultures. A single sample obtained in K3-ethylene-diamine-tetracetic acid 
(EDTA-K3) tube of 4mL was used for cell cycle and immunophenotyping studies. 
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EXPERIMENTAL PROCEDURE 
 
The apoptosis, immunophenotyping and cell cycle experiments were performed by flow 
cytometry in Cytometry Laboratory (Clinical Haematology Department CHP). 
Cytogenetic studies of chromosome instability were performed in the Laboratory of 
Cytogenetics (Department of Microscopy/ICBAS-UP). 
 
Cell cultures 
Whole blood (WB) samples collected in sodium heparin tubes were used to perform cell 
cultures. In each cell culture 0,5ml of WB was set up in RPMI 1640 (Sigma) complete medium 
supplemented with 15% Fetal Bovine Serum (FBS) (Gibco), antibiotics (10,000 units/ml of penicillin 
and 10,000 µg/ml of streptomycin) (Gibco) and 29mg/ml of L-glutamine (Sigma). To stimulate 
cellular division 5 µg/ml of phytohaemagglutinin (Gibco) was used and cultures were placed in an 
incubator at 37ºC with 5% CO2 atmosphere. 
Exposure to BLM and Venofer® 
Bleomycin (BLM) (TEVA Pharmaceutical Industries Ltd.), 15000U/ml, was diluted in RPMI 
1640 to obtain a final concentration of 3.33 g/ml in a final volume of 8ml. Similarly Venofer® was 
prepared in RPMI 1640 to obtain a final concentration of 500g/ml in culture, with the same final 
volume specified above.  
The drugs (Venofer® and BLM) were added after 24h the initiation of cell cultures. For each 
patient and control four different cultures were performed. In one of the tubes, only Venofer® was 
added and in other only BLM was added.  In a third tube, it was added BLM one hour after the 
addition of Venofer®. The remaining culture had no addition of any additive. The obtained cultures 
were: 
1. without any additive 
2. with Venofer® 
3. with BLM 
4. with Venofer® plus BLM 
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T-Cell immunophenotyping 
Protocol: T-Cell immunophenotyping was performed using a non-wash whole blood direct 
immunofluorescence staining method. The blood sample was incubated with fluorescein 
isothiocynate (FITC)-conjugated mouse anti-CD45 pan leukocyte antigen, R-phycoerythrin (R-PE)-
conjugated mouse anti-CD4, phycoerythrin-Texas Red (PE-Texas Red)-conjugated mouse anti-CD8 
and phycoerythrocyanin5 (PC5)-conjugated mouse anti-CD3 mAb (Beckman Coulter, BC),  followed 
by phosphate buffer saline (PBS) wash. The staining was obtained with FITC-conjugated rabbit anti-
mouse IgG (Dako A/S) polyclonal Ab which allows the amplification of the signal. 
The Immunoprep™ Reagent System (BC) was used according to the manufactures’ 
instructions. This kit allowed to lyse the red blood cells with the reagent A, stopping the lysis process 
with reagent B and leukocytes fixation with reagent C.  
Then, using Navios™ flow cytometer (BC) samples were acquired. 
Data analysis: As mentioned earlier “Multicyle AV for Windows™ - DNA Cell Cycle 
Analysis Software” (Phoenix Flow System, PFS) was used to analyse store listmode data. The 
percentage total T cells and CD4+ and CD8+ T cell subsets was calculated based on the following 
principles: 
• Total T cells: low SSC signal, CD45+ high, CD3+ high, among total lymphocytes; 
• CD4+ T-cells: low SSC signal, CD45+ high, CD3+CD4+ high, gated on T-cells; 
• CD8+ T-cells: low SSC signal, CD45+ high, CD3+CD8+ high, gated on T-cells; 
Cell Cycle Studies 
Protocol: The protocol is identical in both EDTA-whole blood and culture samples. Samples 
were incubated with FITC-conjugated mouse anti-CD3 (BC) followed by PBS wash and stained with 
FITC-conjugated rabbit anti-mouse IgG polyclonal Ab (Dako A/S). After another wash with PBS, 
DNA PREP Reagents Kit™ (BC) was used to basic cellular DNA measurement bases on flow 
cytometry, according to the protocol described by Lima M et al. (1). Incubation times and conditions 
were carefully respected. 
The DNA stain using Coulter® DNA PREP Reagents Kit™ (BC) was executed in two steps. 
First, a DNA PREP LPR reagent that contains non-ionic detergents for cell permeabilization was 
used. Second, double stain nucleic acids, DNA and dsRNA, were stained with propidium iodide. 
Then, samples were read on Navios™  flow cytometer (BC). 
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Data analysis: To analyse store listmode data “Multicyle AV for Windows™ - DNA Cell 
Cycle Analysis Software” (Phoenix Flow System, PFS), specific for DNA analysis, was used. With 
this program the percentage of CD3+ T-cells in the different phases of the cell cycle (G0/G1, S and 
G2/M) was calculated, based on the measurement of the amount of DNA. 
Apoptotic T cell evaluation 
Protocol: For apoptotic T-cells study mononuclear peripheral blood cells were used. The 
protocol is identical in both EDTA-whole blood and culture samples. To separate this cells from the 
rest of the components of the blood it was used Lymphoprep™ (Nycomed Pharma AS, Oslo, 
Norway), a 1.077 g/ml density gradient that by centrifugation allows to obtain an isolated ring of 
mononuclear cells that were extracted. Then, mononuclear cells were washed and suspended in RPMI 
culture medium and kept overnight in the refrigerator before further processing. On the next day, the 
sample was incubated with PE-conjugated mouse anti-CD3 and washed with PBS. Then using the 
Annexin V-FITC/7-AAD kit® (BC) the cells were incubated with the different antibodies contained 
in the kit according to the manufacturer bulla. Conditions and times of incubation were strictly 
adhered. Samples were acquired with NaviosTM flow cytometer (BC). 
The percentages of CD3+ T-Lymphocytes in different apoptotic status were calculated based 
on the following principles: 
• Viable cells: Annexin V-negative/7-AAD-negative 
• Early apoptotic: Annexin V-positive/7-AAD-negative 
• Late apoptotic or already dead: Annexin V-positive/7-AAD-positive 
 
Cytogenetic analysis - evaluation of chromosome instability  
After 72h of culture, cells were harvested after 1h incubation with 100l colcemid® (Gibco) 
followed by hypotonic treatment with 75mM KCl and fixation in 1:3 solution of acetic acid:methanol. 
Chromosome preparations were made by “air drying method”. Chromosomes were stained with a 
solution of Giemsa (Gibco), 4% in PBS, during 5 minutes. 
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A 
 
B 
C 
 
D 
 
E F 
Figure 1. Chromosome aberrations evaluated in cytogenetic experiments (amplification 100x): A - metaphase with a gap 
(arrow); B – metaphase with a break (arrow); C – metaphase with a figure (arrow); D – metaphase with a dicentric 
chromosome (arrow) and an acentric fragment (arrowhead); E -  metaphase with a ring chromosome (arrow); F – 
pulverized metaphase where it is possible visualize Venofer® residues (*). 
 
* 
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Cytogenetic analysis was performed on coded slides. Fifty metaphases were analysed for each 
culture. To avoid bias in cell selection, consecutive metaphases, which appeared intact with sufficient 
well-defined chromosome morphology, were selected for the study. Each metaphase was scored for 
the number of structural abnormalities (Figure 1). Achromatid areas less than a chromatid in width 
were scored as gaps and achromatic areas more than a chromatid in width, were scored as breaks. 
Rearrangements, consisting in tri-radial and quadri-radial configurations, dicentric and ring 
chromosomes, were scored with the number of breaks necessary to form these morphological 
structures, generally two breaks. Gaps were excluded from the score. 
To evaluate chromosome instability two cytogenetic indices were used: percentage of aberrant 
cells and number of breaks per cell. 
 
Evaluation of Proliferative index 
At 72 hours of culture 25 microliters of each tube were extracted and were diluted by a factor 
of 1:4. Then it was proceeded the final cell count per unit of volume in a Neubauer chamber 
(haemocytometer). Subsequently these values were compared with the lymphocyte count per unit 
volume obtained by automatic blood cell counter (BC) before culture. Proliferative index was 
obtained dividing the total final cell count by the total initial cell count. 
Statistical analysis 
Differences in group means were tested by Student’s t-test or the Mann-Whitney-test as 
appropriate according to the variable distribution. Differences in sample distributions were tested by 
the Kolmogorov-Smirnov test. Correlations between variables were evaluated by simple linear 
regression. Graph results are expressed as Mean  standard deviation of the mean (SDM). 
Data were analysed by StatGraphics software (STATGRAPHICS® Centurion XVII, version 
17.1.06) and P values lower than 0.05 were considered statistically significant. 
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RESULTS 
Changes in cell cycle and proliferative index following Venofer® exposure 
The effect of Venofer on T lymphocyte cell cultures was addressed through the analyses of 
cell cycle phase relative distribution, evaluation of apoptotic cells, and measure of the proliferative 
index and the cytogenetic parameters of genotoxicity: number of breaks per cell and percentage of 
aberrant cells. The results are shown in table 3. 
In the presence of Venofer® it was observed a consistent and significant increase in the 
relative proportion of T lymphocytes in G0 / G1 phases of cell cycle (p-value=0.0137) with a 
corresponding significant decrease in the proportion of cells in S phase (p-value=0.0228). No 
significant differences were observed either in the relative proportion of cells in G2 / M phases or the 
percentage of apoptotic cells. The T lymphocyte proliferative index was also significantly lower in 
the presence of Venofer® (p-value=0.0242). It was not observed any impact of Venofer® on 
genotoxicity as measured by cytogenetic markers.  
 
Table 3. Comparisons of the cell cycle, apoptosis and cytogenetic parameters in T lymphocytes from normal healthy 
controls according to the presence (+Ven) or the absence (-Ven) of Venofer® in the culture medium. Results are displayed 
as individual values and summarized as the mean and standard deviation of each group. Differences between groups were 
tested by the paired t-test. 
  
% of cells 
in G0/G1 
 
% of cells 
in S 
 
% of cells 
in G2/M 
 
% of 
apoptotic 
cells 
 
Proliferative 
Index 
 
Number of 
breaks per 
cell 
 
% of 
aberrant 
cells 
Individuals  Ven- Ven+  Ven- Ven+  Ven- Ven+  Ven- Ven+  Ven- Ven+  Ven- Ven+  Ven- Ven+ 
1  56.8 89.4  32.1 10.6  11.1 0.0  92.0 94.8  4.42 1.75  0.04 0.02  2 2 
2  41.1 57.2  46.3 36.4  12.6 6.4  47.8 75.9  1.75 0.50  0.02 0  2 0 
3  48.6 65.9  48.4 28.2  3.0 5.9  84.7 79.2  2.22 0.98  0 0  0 0 
4  74.8 89.7  21.6 9.3  3.6 1.0  62.3 35.2  1.11 1.17  0 0.06  0 6 
5  76.3 77.1  16.9 20.0  6.8 2.9  57.5 53.3  1.85 1.04  0.02 0.04  2 4 
6  80.6 92.4  16.9 7.1  2.5 0.5  55.5 56.8  4.93 2.04  0 0.08  0 4 
Mean  
SD 
 
63.0 
16.4 
78.6 
14.5 
 
30.4 
14.3 
18.6 
11.8 
 
6.6 
4.4 
2.8 
2.8 
 
66.7 
17.6 
65.9 
21.4 
 
2.71 
1.57 
1.25 
0.56 
 
0.01 
0.02 
0.03 
0.03 
 
1.0 
1.1 
2.7 
2.4 
Significance 
level 
(p-value) 
 0.0137  0.0228  n.s.  n.s.  0.0242  n.s.  n.s. 
Abbreviations: SD: standard deviation; n.s. not statistically significant 
 
No significant correlations were observed between the number of lymphocytes, or their 
specific populations (number of CD4+ or CD8+ T-cells), and any of the parameters for cell cycle, 
apoptosis or chromosome instability. 
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No impact of Venofer® in cell cycle, apoptosis, proliferative index and chromosome instability 
parameters in HH patients 
The effect of Venofer® on cultures of T lymphocytes obtained from HH patients was 
analysed. The results are shown in table 4. In contrast with the results observed in controls (see 
above), no significant impact of Venofer® was observed on any parameters evaluated.  
 
Table 4. Comparisons of the cell cycle, apoptosis and cytogenetic parameters in T lymphocytes from Hereditary 
Haemochromatosis patients controls according to the presence (Ven+) or the absence (Ven-) of Venofer® in the culture 
medium. Results are displayed as individual values and summarized as the mean and standard deviation of each group. 
Differences between groups are tested by paired t-test. 
  
% of cells 
in G0/G1 
phases 
 
% of cells 
in S phase 
 
% of cells 
in G2/M 
phases 
 
% of 
apoptotic 
cells 
 
Proliferative 
Index 
 
Number of 
breaks per 
cell 
 
% of 
aberrant 
cells 
Individuals  Ven- Ven+  Ven- Ven+  Ven- Ven+  Ven- Ven+  Ven- Ven+  Ven- Ven+  Ven- Ven+ 
1  69.3 87.5  22.5 12.5  8.2 0.0  82.4 70.5  3.62 4.94  0.06 0.02  4 2 
2  51.0 51.7  37.9 42.7  11.1 5.6  35.4 34.9  1.85 1.24  0.16 0.08  2 6 
3  51.4 56.2  39.6 37.0  9.0 6.8  50.9 74.6  0.63 0.68  0.04 0.04  4 2 
4  68.1 68.5  25.5 26.4  6.4 5.1  89.3 76.5  2.13 1.00  0 0  0 0 
5  76.9 73.2  17.8 20.3  5.3 6.5  49.7 79.3  0.41 0.21  0 0  0 0 
6  62.8 68.8  27.7 25.8  9.5 5.4  86.0 79.5  2.18 1.91  0 0  0 0 
Mean 
SD 
 
63.3 
06.4 
67.7 
12.7 
 
28.5 
8.6 
27.5 
11.0 
 
8.3 
2.1 
4.9 
2.5 
 
65.6 
23.0 
69.2 
17.1 
 
1.80 
1.17 
1.66 
1.70 
 
0.04 
0.06 
0.02 
0.03 
 
1.7 
1.9 
1.7 
2.3 
Significance 
level 
(p-value) 
 n.s.  n.s.  n.s.  n.s.  n.s.  n.s.  n.s. 
Abbreviations: SD: standard deviation; n.s. not statistically significant 
 
Such as in controls, no significant correlations were observed between the number of 
lymphocytes, or their specific populations (number of CD4+ or CD8+ T-cells), and any of the 
parameters for cell cycle, apoptosis or chromosome instability. 
An illustration of the overall difference between HH patients and controls is given in figure 2 
were Venofer® induced G0/G1 phase variation is shown, in both healthy controls and HH patients. 
This parameter was calculated by dividing the percentage of cells in G0/G1 phase in the presence of 
Venofer® and the percentage of cells in G0/G1 phase in the absence of Venofer® in each individual 
and was assumed to reflect the extension of increment in the G0 / G1 phase of cell cycle induced by 
Venofer®. 
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Figure 2. Comparison between HH patients and controls for a ratio that reflects the magnitude of the difference in the 
percentage of cells in G0/G1phases induced by Venofer®. 
 
Changes in the bleomycin genotoxicity test following Venofer® exposure 
In order to test the hypothesis that the effect of Venofer® on T lymphocytes cell cultures could 
be due to an increased availability of intracellular iron, bleomycin genotoxicity test was used. For 
that purpose bleomycin-induced T cell cultures were performed, in the same individuals as above, in 
the presence or absence of Venofer®.  The results are shown in table 5.  
 
Table 5. Bleomicyn genotoxicity test following Venofer® exposure expressed as the percentage of breaks per cell and 
percentage of aberrant cells in cell cultures from both healthy controls and Hereditary Haemochromatosis patients.  
  Controls  HH patients 
  
% of aberrant cells  
Number of breaks per 
cell 
 % of aberrant cells  
Number of breaks per 
cell 
Individuals  Ven- Ven+  Ven- Ven+  Ven- Ven+  Ven- Ven+ 
1  45 15  1.02 0.23  39 8  0.76 0.34 
2  44 26  0.94 0.66  42 20  0.72 0.43 
3  32 22  0.80 0.29  40 20  1.58 0.50 
4  32 26  0.74 0.62  38 28  0.80 0.53 
5  46 18  0.92 0.33  40 16  1.08 0.27 
6  36 22  0.92 0.63  44 18  0.90 0.39 
Mean 
 SD 
 39.1 
6.5 
21.5 
4.4 
 
0.89 
0.10 
0.46 
0.19 
 
40.5 
2.2 
18.3 
6.5 
 
0.97 
0.32 
0.41 
0.10 
Level of 
significance 
(p-value) 
 
0.0065  0.0077  0.0006  0.0076 
Abbreviations: SD: standard deviation. 
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A highly significant decrease in the percentage of aberrant cells (p=0.0065) and the number 
of breaks per cell (p=0.0077) was observed in Venofer® added cultures in healthy controls. Similarly, 
it was also observed a highly significant decrease in the percentage of aberrant cells (p=0.0006) and 
the number of breaks per cell (p=0.0076) were observed in HH patients. In these test conditions no 
significant differences were observed between HH patients and controls. 
Cell cycle and apoptosis parameters were also evaluated in cultures with bleomycin with or 
without Venofer® in both controls and HH patients. The results are expressed in tables 6 and 7, 
respectively. No significant differences were observed in any of the conditions tested with the 
addition of Venofer®, in both controls and HH patients. 
 
Table 6. Distribution of CD3+ T-lymphocytes through the different phases of the cell cycle and percentage of apoptotic 
cells in bleomycin test cultures with (Ven+) and without (Ven-) Venofer® in controls .  
  % of cells in G0/G1  % of cells in S  % of apoptotic cells 
Individuals  Ven- Ven+  Ven- Ven+  Ven- Ven+ 
1  68.0 80.7   23.9 18.2   75.5 98.4 
2   66.9 68.7   22.9 23.6   54.7 54.8 
3  62.1 55.5   29.8 29.2   59.3 57.9 
4   77.8 80.4   14.8 14.4   58.8 53.1 
5  92.9 87.5   6.2 9.1   28.2 52.1 
6   67.7 84.1   24.5 11.5   72.3 62.2 
Mean 
SD 
  72.6 
11.2 
76.2 
11.9 
 
20.4 
8.4 
17.7 
7.6 
 
58.1 
16.8 
63.0 
17.7 
Level of 
significance 
(p-value) 
 n.s.  n.s.  n.s. 
Abbreviations: SD: standard deviation; n.s. not statistically significant 
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Table 7. Distribution of CD3+ T-Lymphocytes through the different phases of the cell cycle and percentage of apoptotic 
cells in bleomycin test cultures with (Ven+) and without (Ven-) Venofer® in HH patients.  
  % of cells in G0/G1  % of cells in S  % of apoptotic cells 
Individuals  Ven- Ven+  Ven- Ven+  Ven- Ven+ 
1  78.4 75.6   21.6 24.4   72.1 73.7 
2   64.6 69.3   25.7 27.1   30.4 51.9 
3  59.3 67.8   26.7 21.0   68.4 47.6 
4   69.7 75.9   21.4 20.3   76.3 68.8 
5  83.5 81.2   10.6 12.2   55.1 71.9 
6   72.6 88.6   18.0 9.3   76.6 48.6 
Mean 
SD 
  71.4 
8.9 
76.4 
7.7 
 
20.7 
5.9 
19.1 
6.9 
 
63.2 
17.9 
60.4 
12.3 
Level of 
significance 
(p-value) 
 n.s.  n.s.  n.s. 
Abbreviations: SD: standard deviation; n.s. not statistically significant  
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DISCUSSION 
The several applications of iron oxide nanoparticles (IONs) are currently an interesting focus 
of research.  A full characterization of the biological response to these type of materials seems 
fundamental for a better understanding how different cells handle these nanoparticles, to clarify 
putative mechanisms of toxicity and to discover possible new applications (2). There is, however, a 
remarkable lack of information about the mode how peripheral blood cells handle these particles. One 
should note that circulating cells are the first ones entering in contact with the iron oxide particles 
when these are administered intravenously; therefore they are potentially the first target of the 
nanoparticles. This question motivated the present study which was aimed to analyse the in vitro 
effect of Venofer® on the proliferation of peripheral blood T lymphocytes. 
The first relevant result obtained in this study was the demonstration of a significant increase 
in the percentage of lymphocytes at the G0/G1 phase of the cell cycle when they were cultured for 
72 hours in the presence of Venofer®. The fact that the increase of cell numbers at this phase of the 
cell cycle appears to be inversely related with relative proliferative index is suggestive that sucrose-
coated iron oxide nanoparticles may induce a cell cycle arrest at G0/G1 phase. It is well known that 
proper progression through the cell cycle, in eukaryotic cells, is highly monitored by certain 
checkpoints that prevent the cell entering the next phase of division whenever there is any change or 
damage in the components of the cell structure, particularly the DNA. This mechanism is critical to 
prevent certain acquired errors to be transmitted to the daughter cells. In order to control cell cycle 
progression there are three major checkpoints, G1–S, intra-S, and G2–M, which are essentially 
controlled by cyclins and cyclin-dependent kinases (3). These results showing an increase in the 
percentage of cells at the G0/G1 phases with no impact on apoptosis or genotoxicity strongly suggest 
the existence of an effective G1-S checkpoint activation and a G0/G1 cell cycle arrest to prevent 
damage in response to Venofer®. Other studies have accessed before the interference of iron oxide 
nanoparticles in the cell cycle (summarised in table 10). These studies, however, used different 
models, different cell types and different kinds of iron oxide nanoparticles, therefore the results are 
not absolutely comparable. Park et al (2014) using Bare-Iron Oxide Nanoparticles in a mouse 
macrophage cell line also demonstrate a G1 phase cell cycle arrest but, in contrast with this study, 
there was also a dose dependent decrease in cell viability (4). In contrast, Liu et al (2011) did not 
demonstrate any significant effect of IONs on cell viability, apoptosis, cell cycle or proliferation in a 
set of different non-hematopoietic cell lines (RAW264.7, Hepa1-6, HL-7702, and HeLa) but verified 
a significant increase in apoptosis for high doses in others (THP-1 and HepG2) (5). Altogether, these 
studies show that the effect of iron oxide nanoparticles can differ depending on certain factors, such 
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as, drug dose, coating material and the kind of evaluated cell. Further studies with Venofer® may 
prove to be useful to better establish the critical conditions to either induce an effective physiological 
response to the iron induced stress or to induce toxicity. 
 
Table 8. Studies that access Iron Oxide Nanoparticles (IONs) effect on cell cycle. 
Type of ION Size of IONs (nm) Cell line Findings Study/reference 
Bare-Iron Oxide 
Nanoparticles 
 
Unknown 
 
RAW264.7 cells 
(mouse peritoneal 
macrophage cell 
line) 
 
Cell viability decreased in a dose-dependent 
manner after bare-ION exposure, in parallel 
with a G1 phase arrest. 
Park et al. 2014 
(4) 
 
Dimercaptosuccinic 
acid -coated Fe3O4 
magnetic 
nanoparticles 
 
11 
RAW264.7, Hepa1-
6, HL-7702, and 
HeLa 
IONs did not produce any significant effect on 
viability, apoptosis, cell cycles and 
proliferation at any dose. 
 
Iron loading of RAW264.7 was significantly 
higher than that of other cells at any dose. 
Liu et al. 2011 
(5) 
THP-1 and HepG2 
Significant apoptosis at highest concentration 
of IONs (100 µg/mL). 
 
The second relevant result obtained with this study was the demonstration that the pattern of 
cell cycle arrest found in normal healthy subjects was not observed in gender and age matched HH 
patients. This finding is in accordance with the existence of some kind of “adaptive cell response” in 
HH patients that could increase the expression of protective proteins necessary to prevent the harmful 
effects of iron, including oxidative stress effects. Relevant to this interpretation is the evidence 
provided before of a lower frequency of diepoxybutane-induced chromosome instability in HH 
patients as compared to both controls and patients with secondary haemochromatosis (6). Some other 
studies have also suggested the existence of stress adaptive mechanisms in HH. Martineli et al (2013) 
have shown a significant increased hepatic Paraoxonase-1 protein expression in HH patient together 
with a decrease in serum Paraoxonase-1 activity (7). This enzyme hydrolyze lipid peroxides and has 
a major role in protecting cells from inflammatory and oxidative stress (8) and it is known  that 
elevated levels of Paraoxonase-1, can be protective against carbon tetrachloride-induced liver damage 
(9). Recently, Silva-Gomes et al. have shown that the oxidative stress induced transcription factor 
Nrf2 modifies the expression of liver disease in dietary-induced iron overload but, so far, no evidence 
has been provided yet of a similar effect in the human model of HH (10). Another possible mechanism 
to explain the difference in the cellular response of HH patients is related to the facts that hepcidin 
can regulate the intracellular iron levels in T lymphocytes by reducing ferroportin expression on the 
cell membrane and consequently influence lymphocyte proliferation (11) and it is known that HFE-
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related HH patients have low levels of serum hepcidin. In this context, T-lymphocytes of HH patients 
could have higher ferroportin mediated iron export which could maintain a lower level of intracellular 
iron. It is important to mention that all the mechanisms proposed so far could only explain our findings 
assuming that T-lymphocytes somehow internalize and process the sucrose-coated iron oxide 
nanoparticles to interact with intracellular pathways. To clarify this, we had proposed to observe these 
cells through TEM/EDX technology but these experiments could not be done because of lack of 
financial support. Future studies are needed to complete this part of the project. 
One of the limitations of the present study was the low number of patients tested, which may 
compromise the significance and interpretation of some results. For example, although in lymphocyte 
cultures from HH patients the number of cells in G0 / G1 phases appears to be higher in cultures with 
Venofer® than in cultures with no additive, this difference was not statistically significant. Also, 
when it was compared the overall G0/G1 phase variation induced by Venofer® between patients and 
controls (Figure 2), in spite of the apparent marked difference, this was also not statically significant, 
due to the impact of one individual (individual 1 in Table 4) who showed a response similar to 
controls. Apart from the possibility of this individual being an “outlier” (it is not possible to assume 
that with only 6 individuals studied), this could also be explained by heterogeneity among HH patients 
in their phenotypic expression, such as happens with other clinical manifestations. It is known that 
the penetrance of the p.Cys282Tyr mutation is largely variable (12). For example, in some north-
Europe populations it is possible to find a prevalence of homozygous for the p.Cys282Tyr mutation 
of about 0.5% (13) although only a minority develop clinically apparent disease. Likewise, the natural 
history of the disease may range from a small change in iron parameters to terminal liver disease with 
cirrhosis or other manifestations of advanced disease (14). Age and gender are important features that 
can modulate clinical expression of the disease, but there are certainly many other still unidentified 
factors. Importantly, it was demonstrated that a high number of CD8+ T-cells is a protective factor for 
the clinical consequences of the disease (15). Although the total numbers of lymphocytes and relative 
proportions of CD8+ T and CD4+ T cells was not found in this study to be correlated with the response 
to Venofer®, the number of patients studied was too small to drive a definite conclusion. It would 
thus be important to extend this study by increasing the sample size, which would make possible to 
clarify if there is indeed an overall significant difference between HH patients and controls or to 
discriminate among differentially expressing HH patients. 
Finally one must discuss the unexpected findings obtained when bleomycin genotoxicity test 
was applied the. This test was chosen to test the hypothesis that the observed effect of Venofer® was 
dependent on the availability of intracellular iron. This chemotherapeutic agent needs a simultaneous 
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biding to a redox-active metal ion such as Fe2+ or Cu+, as well as molecular oxygen to cause DNA 
damage and consequently chromosome instability (16). The assumption was that, if levels of 
intracellular iron were increased after incorporation of IONs, more iron would be available for redox 
reactions and therefore the genotoxic effect of bleomycin should be increased in the presence of 
Venofer®. Surprisingly, in these experimental conditions, cultures with bleomycin plus Venofer® 
had a highly significant reduction in the percentage of chromosome breaks per cell as well as in the 
percentage of aberrant cells as compared to cultures with bleomycin alone. In addition, it was not 
observed, in these culture conditions, any significant effect on the formerly described cell cycle arrest 
in G0/G1 induced by Venofer®. So far, there is no explanation for these findings. One possibility is 
that the added effect of Venofer® and bleomycin in the culture medium may change completely the 
culture conditions, eventually by the formation of new iron-bleomycin complexes which would no 
longer act upon the cultured cells. It is know that bleomycin binds to NTBI in solution (17). Whether 
NTBI is found in the culture medium in the presence of Venofer®, this was not tested in this study. 
Another possibility to consider is that, since bleomycin also is known to induce a cell cycle arrest at 
G0/G1 (18), the effect of Venofer® would be no longer significant. It should be noted, however, that 
all the above described explanations are merely speculative. In order to explain the mechanism 
involved more experiments would be required, which are out of the scope of this work. 
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CONCLUSION 
In summary, this study allowed us to approach, for the first time, a biological response of T-
lymphocytes to sucrose-coated iron oxide nanoparticles, i.e., a possible protective cell cycle arrest at 
G0/G1. The study also showed that this response is different in normal healthy subjects and in HH 
patients suggesting that these individuals, by remaining in a constant state of iron overload, may have 
induced an adaptive response that makes them less susceptible to the effects of this metal. However 
some of the questions initially posed have not been answered yet. It would be fundamental to perform 
the TEM/EDX experiments to evaluate if the nanoparticles are indeed internalized by T-cells and, in 
that case, what is their intracellular composition and localization. Further gene expression studies are 
also important to carry out in future, in order to identify the putative intracellular molecular pathways 
involved in the adaptive response of HH patients. Following this work will also be important to 
increase our knowledge about the heterogeneity of this disease as well as understanding the 
physiological role of T lymphocytes in iron metabolism.  
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